Next Article in Journal
Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Autoimmune Rheumatic and Non Rheumatic Diseases
Previous Article in Journal
Eosinopenia as a Prognostic Biomarker for Noninvasive Ventilation Use in COPD Exacerbations
 
 
Article
Peer-Review Record

Nasal Cytology on 241 Children: From Birth to the First 3 Years of Life and Association with Common Airways Diseases

J. Pers. Med. 2023, 13(4), 687; https://doi.org/10.3390/jpm13040687
by Cecilia Rosso 1,2,*, Federica Turati 3, Alberto Maria Saibene 1,2, Elvira Verduci 4, Emanuela Fuccillo 1, Maria Chiara Tavilla 1, Mauro Magnani 5, Giuseppe Banderali 6, Monica Ferraroni 3,7, Eugenio De Corso 8, Giovanni Felisati 1,2 and Carlotta Pipolo 1,2
Reviewer 1:
Reviewer 2:
J. Pers. Med. 2023, 13(4), 687; https://doi.org/10.3390/jpm13040687
Submission received: 20 March 2023 / Revised: 12 April 2023 / Accepted: 17 April 2023 / Published: 19 April 2023
(This article belongs to the Section Personalized Therapy and Drug Delivery)

Round 1

Reviewer 1 Report

This is a very interesting work regarding the nasal cytology during the first years of life and its association to several outcomes, such as atopy and respiratory infections.

Nebvertheless, I have some comments to make.

In line 31 please correct the word "realated" into "related".

In line 32 the medical abbreviation "AOM" must be explained.

In lines 73-74 I believe a citation is missing.

Lines 99-111 should be changed into one structured paragraph, and not in "bullet form" as in protocols.

The "Methods" and "Statistical Analysis" sections are presented excellently.

The presentation of the results is sound.

In line 22 please rephrase "is still little investigated".

In line 361 change "if" to "of".

Athough the Discussion is well structured you should add Conclusions to your manuscript.

Author Response

please see the attachment

Author Response File: Author Response.docx

Reviewer 2 Report

The authors have assessed nasal cytology at birth, first year, and third year of life and correlated various factors with nasal cytology and clinical outcomes at 3 years of age.

The study is of interest, though many factors studied were not of statistical significance. One of the reasons is the dropouts during the study, with COVID playing its part in reducing participation.

General comments:

Spelling and grammar need to be improved

Specific comments:

Please mention what questionnaire was used to assess the clinical outcomes and who developed it. Whether any previously validated questionnaires such as ISAAC/GAN? What language was it administered? It is important to confirm the questions measure what it is supposed to measure and that is the reason a validated questionnaire is critical for a good study.

Caesarean section: 36+17 is not 55. please check the numbers in the table. This cannot be missing data.

Please mention how each of the clinical outcomes was diagnosed in the methodology. For example, how was asthma diagnosed in children 1-3 years of age? Other conditions as well. 

Please define what is ++++, +++ etc

 

In Table 3 ciliated cells are not discussed

 

How was the rhiocytogram validated for its reproducibility? Again, this is an extremely important aspect critical for the success of the study. Sputum induction studies are rarely performed as they are very difficult to standardize. Similarly, establishing reproducibility would be critical. Please explain in methods section, how this was done

 

Line 326 -329: please modify this statement. It needs a microbiome analysis and just a smear is not sensitive enough to comment on bacteria. Please replace microbiological analysis with microbiome analysis

 

 

Author Response

Please see the attachment

Author Response File: Author Response.docx

Round 2

Reviewer 2 Report

The authors have addressed the clarifications adequately

Back to TopTop